Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Women Contraception Clear all

Conditions: CKD, Chronic Kidney Diseases
Interventions: Decision aid, Standard handout; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Contraception, HIV
Interventions: Levonorgestrel and Ethinyl Estradiol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: Misoprostol, Magnesium Oxide; Drug · Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 20 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions: Nestorone + Testosterone Combination Gel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Contraception
Interventions: NES/EE CVR; Combination Product
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more

Conditions: Hemostasis, Oral Contraceptive
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more

Conditions: Intrauterine Device Complications, Contraceptive Device Failure, IUD Fragmentation, Retained Intrauterine Device, Female Contraception, Women's Health, Reproductive Health
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 44 participants
Timeline: 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Contraception
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Contraceptive Usage, Contraception
Interventions: SexHealth Mobile; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Kansas City, Missouri

Conditions: Obesity
Interventions: Levonorgestrel-based emergency contraception 1.5 mg, Levonorgestrel-based emergency contraception 3.0mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral combined hormonal contraceptives; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years to 49 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Epilepsy
Interventions: Non-interventional; Other
Lead sponsor: Neuroendocrine Associates P.C.; Other
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Wellesley, Massachusetts • New York, New York

Conditions: Contraception
Interventions: 15 mg E4/3 mg DRSP; Drug
Lead sponsor: Estetra; Industry
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 2,148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Systemic Lupus Erythematosus, Contraception
Interventions: HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention, Routine Care; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions: EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,887 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 85
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more

Conditions: Attitudes
Interventions: Contraception Information Packet; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Unplanned Pregnancy
Interventions: Counseling Intervention; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 15 Years to 29 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraceptive Usage, Coagulation
Interventions: DHEA Oral Capsule, Placebo Oral Capsule; Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Substance Use Disorders, Pregnancy Related, Contraception
Interventions: MyPath Intervention, Usual care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sterilization, Female, Fallopian Tube Occlusion
Interventions: Hysterosalpingogram (HSG); Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraception
Interventions: TV-46046, Depo-subQ Provera; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Search by objective public record fields.

Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Misoprostol With Intrauterine Device Insertion

Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

Patient Factors Associated With Fragmentation of Copper Intrauterine Device (IUD) Requiring Hysteroscopic Removal

A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

SexHealth Mobile: Integrating a Mobile Clinic and a Point-of-care Contraception Counseling and Access

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG

Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Epilepsy Birth Control Registry

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Pilot of Social Network Intrauterine Contraceptive (IUC) Intervention

Use of Motivational Interviewing to Increase Contraception Use Among Young Women

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum Period

Development of an Intrauterine Pressure Threshold to Confirm Tubal Occlusion

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age